Sorafenib therapy provided limited benefits for the overall progression-free survival (PFS) of RCC patients (Fig. 7a), while patients with high ANGPTL3 expression levels in their tumours had a more significant improvement in PFS after receiving sorafenib than those in the control group did. Here, ANGPTL3 is linked to neoplasm.